Marker Therapeutics, Inc. (MRKR)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Marker Therapeutics, Inc. reported revenue of $3.55M, down 46.2% from the prior year. The company ran a net loss, with a net margin of -343.0%. It held $19.07M in total assets against $2.27M in total liabilities.
Key ratios (FY2025)
-363.5%
Operating margin
-343.0%
Net margin
-72.4%
Return on equity
-46.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.55M | $6.59M | $3.31M | $3.51M | $1.24M | $466.8K | $213.2K | — | — | — |
| Operating Income | -$12.89M | -$11.12M | -$14.58M | -$19.79M | -$39.48M | -$28.89M | -$22.53M | -$148.17M | -$11.48M | -$8.49M |
| Net Income | -$12.16M | -$10.73M | -$8.24M | -$29.93M | -$41.88M | -$28.71M | -$21.43M | -$147.96M | -$10.98M | -$2.46M |
| EPS (Diluted) | $-0.79 | $-1.19 | $-0.94 | $-3.58 | $-5.47 | $-0.61 | — | — | $-1.16 | $-0.72 |
| Total Assets | $19.07M | $22.02M | $17.13M | $34.42M | $68.14M | $45.61M | $46.36M | $62.14M | $5.18M | $7.92M |
| Total Liabilities | $2.27M | $3.46M | $3.07M | $14.82M | $24.15M | $18.27M | $2.27M | $2.80M | $1.52M | $1.74M |
| Shareholders' Equity | $16.80M | $18.56M | $14.05M | $19.60M | $43.99M | $27.34M | $44.09M | $59.34M | $3.66M | $6.18M |
| Cash & Equivalents | $16.07M | $19.19M | $15.11M | $11.78M | $42.35M | $21.35M | $43.90M | $61.75M | $5.13M | — |
| Operating Cash Flow | -$12.01M | -$10.91M | -$16.44M | -$26.97M | -$27.28M | -$20.03M | -$18.28M | -$14.48M | -$8.44M | -$6.51M |
| Capital Expenditures | — | — | — | — | — | — | $375.0K | $147.7K | $0 | — |
| Shares Outstanding | 16.70M | 10.70M | 8.90M | 8.40M | 8.30M | 50.70M | 45.70M | 45.40M | 10.60M | 8.40M |